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Summary
To identify human genes required for tumor cell growth, transcriptome-scale selection was used to isolate genetic suppres-
sor elements (GSEs) inhibiting breast carcinoma cell growth. Growth-inhibitory GSEs (cDNA fragments that counteract
their cognate gene) were selected from 57 genes, including known positive regulators of cell growth or carcinogenesis
as well as genes that have not been previously implicated in cell proliferation. Many GSE-cognate genes encode transcription
factors (such as STAT and AP-1) and signal transduction proteins. Monoclonal antibodies against a cell surface protein
identified by GSE selection, neural cell adhesion molecule L1CAM, strongly inhibited the growth of several tumor cell lines
but not of untransformed cells. Hence, selection for growth-inhibitory GSEs allows one to find potential targets for new
anticancer drugs.
Introduction is then introduced into recipient cells, followed by selection for
the desired phenotype and the recovery of biologically active
GSEs from the selected cells. By using a single cDNA as theThe completion of the draft sequence of the human genome
has provided us with a partial list of known and putative human starting material for GSE selection, one can generate specific
inhibitors of the target gene and map functional domains in thegenes, the total number of which is estimated between 30,000
and 45,000 (Lander et al., 2001; Venter et al., 2001). These target protein. By using a mixture of multiple genes or the entire
transcriptome as the starting material, GSE selection allows onegenes provide many potential targets for drugs, some of which
may be useful in stopping the growth of cancers. The develop- to identify genes responsible for a specific cellular function,
since such genes will give rise to GSEs inhibiting this function.ment of new anticancer drugs could be greatly facilitated by
the ability to narrow down the list of human genes to those that For example, GSE selection has been used to identify viral
genes that are essential for the infectious cycle of bacteriophageare necessary for the growth of tumor cells. To find such genes,
we have used a general strategy, which is based on the principle lambda (Holzmayer et al., 1992) or human immunodeficiency
virus (Dunn et al., 1999), and to clone tumor suppressor genesthat genes required for cell proliferation should give rise to ge-
netic suppressor elements (GSEs) that inhibit cell growth. (Garkavtsev et al., 1996), genes that mediate cellular sensitivity
to anticancer drugs (Gudkov et al., 1994; Levenson et al., 1999),GSEs are short biologically active cDNA fragments that in-
terfere with the function of their cognate gene (Gudkov et al., and regulators of transcription (Novoa et al., 2001).
GSEs derived from genes involved in cell proliferation are1999; Roninson et al., 1995). GSEs may encode antisense RNA
molecules that inhibit gene expression or peptides correspond- expected to inhibit cell growth. To select for growth-inhibitory
GSEs, we have used bromodeoxyuridine (BrdU) suicide as theing to protein domains that act as dominant negative inhibitors.
The general strategy for the isolation of biologically active GSEs selection strategy. This strategy has been previously used to
isolate three growth-inhibitory GSEs from a mixture of 19 cDNAsinvolves the preparation of an expression library containing ran-
domly fragmented DNA of the target gene or genes. This library associated with the G0/G1 transition (Pestov and Lau, 1994),
S I G N I F I C A N C E
The development of new anticancer drugs can be greatly facilitated by determining which of the human genes are required for
tumor cell growth. The present study shows that function-based selection of GSEs inhibiting the growth of tumor cells allows one to
generate an extensive list of potential targets for cancer treatment. 57 target genes, many of which were previously unknown to
play a role in cell proliferation, have been identified through this selection. Antibodies against one of the identified gene products,
L1CAM, show a growth-inhibitory activity specific for tumor cells, which demonstrates the power of our strategy for elucidating
promising new targets for cancer treatment.
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Figure 1. Selection of growth-inhibitory GSEs from a normalized cDNA fragment library
A: Scheme of selection.
B: Survival of BrdU suicide selection by library-transduced MDA-MB231 cells, tested immediately after G418 selection, after one round and after two rounds
of BrdU selection in the presence of IPTG. For testing, cells were plated at 200,000 per P100 and subjected to one round of BrdU selection in the absence
or in the presence of 50 M IPTG, and allowed to form colonies for 12–14 days in the absence of IPTG.
which were fragmented and cloned in a regulated plasmid ex- the source of RNA and as the recipient was aimed at identifying
target genes that are more likely to be essential in differentpression vector. To carry out such selection from a library that
would represent the entire transcriptome of breast carcinoma types of breast cancer. Prior to transduction, the recipient cell
line was modified by the introduction of murine ecotropic recep-cells, we have now generated a large library of normalized (re-
duced redundancy) fragments of total cellular cDNA in a retrovi- tor, which renders cells highly infectable with ecotropic retrovi-
ruses, and of modified bacterial LacI repressor that allows forral vector that allows for high-efficiency transduction and isopro-
pyl--thio-galactoside (IPTG)-regulated gene expression in IPTG-regulated gene expression from promoters containing Lac
operator.mammalian cells (Chang and Roninson, 1996). With this library,
we have succeeded in identifying a large set of genes that give Eighty million library-transduced MDA-MB231 cells were
used for two consecutive rounds of BrdU suicide selection. Thisrise to GSEs inhibiting breast carcinoma cell growth. Monoclonal
antibodies against a cell surface protein L1CAM, encoded by selection (Stetten et al., 1977) is based on the destruction of cells
that replicate their DNA in the presence of BrdU, a photoactiveone of these genes, inhibit the growth of several transformed
cell lines but not of untransformed cells, demonstrating that nucleotide that incorporates into DNA and causes lethal DNA
crosslinking upon white light illumination. Prior to BrdU addition,GSE-cognate genes can be regarded as potential new targets
for cancer treatment. cells are treated with IPTG to induce transcription of library-
derived cDNA fragments. Cells containing IPTG-inducible
growth inhibitory GSEs do not replicate their DNA and do notResults and Discussion
incorporate BrdU in the presence of IPTG. Such cells therefore
survive the selection and will proliferate upon the removal ofLibrary construction and selection of growth-inhibitory GSEs
IPTG. The advantages of this method include its sensitivity forThe selection of growth-inhibitory GSEs is schematized in Figure
weak growth-inhibitory GSEs; i.e., even if only a small fraction1A. The normalized cDNA fragment library was generated from
of GSE-containing cells fail to replicate in the presence of IPTG,MCF-7 breast carcinoma cell line (estrogen receptor-positive,
such cells will survive BrdU suicide and will give rise to a recov-wild-type for p53). The cDNA fragments in this library (50–400
ering clone. This technique also allows one to identify and ex-bp size) were tagged by different adaptors at the ends corre-
clude spontaneously arising BrdU-resistant mutants, since theirsponding to the 5 and 3 direction of the original mRNA. The
survival will not depend on the presence of IPTG. As shown in5 adaptor contains translation initiation codons in three open
Figure 1B, two consecutive rounds of selection increased thereading frames, and the 3 adaptor contains stop codons in
number of colonies that survive BrdU suicide in the presenceall the frames. The cDNA fragment mixture was subjected to
of IPTG relative to the absence of IPTG, which is consistentnormalization based on Cot fractionation, using a modified pro-
with successful selection of IPTG-inducible growth-inhibitorycedure of Patanjali et al. (1991) (Gudkov and Roninson, 1997).
GSEs.The normalized cDNA preparation was cloned into IPTG-induc-
ible retroviral vector LNXCO3 in both sense and antisense orien-
tations, producing a library of approximately 50 million clones, Identification of growth-inhibitory GSEs
Genomic DNA was isolated after BrdU suicide selection and87% of which were recombinant. This library was transduced
into breast carcinoma cell line MDA-MB231, which represents used to recover the inserts from integrated proviruses by PCR,
using vector-derived sequences flanking the inserts as primersa more malignant class of breast cancers; it is estrogen receptor-
negative and p53-deficient. The choice of different cell lines as (Gudkov and Roninson, 1997). The PCR-amplified mixture was
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Figure 2. Distribution of selected fragments in individual cDNAs
Positions of the selected sense-oriented (top arrows) and antisense-oriented
(bottom arrows) fragments relative to the cDNA sequence and protein
domains of STAT3, STAT5b, ARHG (RhoG), L1CAM, and ITGB5. GSEs verified
by functional assays and used to generate cell lines are identified by an X.
Domain abbreviations: TAD, transcriptional activation domain; S1, site 1; S2,
site 2; IR, insert region; IgGL, immunoglobulin-like; FNL, fibronectin-like; ICD,
intracellular domain; INB, integrin-; CYS, cystein-rich; CT, C-terminal.
directionally cloned into LNXCO3 to yield a GSE-enriched library
that was then analyzed by high-throughput sequencing. cDNA
sequences were obtained for 1482 inserts. To determine the
Figure 3. Functional assays for growth-inhibitory activity of representativeidentity of the corresponding genes, these sequences were ana-
GSEslyzed using the BLASTMask program that we wrote for sequen-
Results are shown as mean  standard error for two separate experiments,tial BLAST homology searches in NCBI sequence databases.
each performed in triplicate.Through this analysis, 64 known and unknown genes were found A: Clonogenic recovery from BrdU suicide selection in cell populations trans-
to give rise to three or more identical clones or to two or more duced with the indicated GSEs in the presence relative to the absence of
IPTG.different cDNA sequences in the sequenced set. Of these, 21
B: Relative cell number of clonal cell lines transduced with the indicatedgenes were represented by a single cDNA sequence, and 43
GSEs after 7-day growth in the presence relative to the absence of IPTG.genes were represented by 2 to 11 different cDNA sequences.
C: Growth curves of clonal cell lines transduced with the GSEs from STAT3
As in earlier studies (where multiple GSEs were selected and L1CAM, in the presence or in the absence of IPTG.
from a single gene or a viral genome), both sense and antisense- D: Reverse transcription-PCR analysis of RNA expression of STAT3 and L1CAM
GSEs in the cell lines of C, on the indicated days in the presence or in theoriented fragments of the same gene tend to form clusters.
absence of IPTG. -actin was used as a normalization standard.Such clusters indicate selectivity for specific protein domains
or for specific RNA regions susceptible to antisense inhibition. In
some cases, sense-oriented fragments were localized to protein
domains involved in known functional interactions, suggesting
that peptides encoded by these fragments disrupt the corre-
sponding protein interactions. Figure 2 shows the position of
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Table 1. Genes giving rise to growth-inhibitory GSEs
Accession # Sequences Functional
Gene Number (s/as) # clones Gene function Association with cancer assays*
Transcription factors
STAT5b NM_012448 4(s), 4(as) 152 Transcription factor (involved in Implicated in lymphomagenesis A, B
hematopoietic cell growth)
STAT3 NM_003150 4(s), 3(as) 25 Transcription factor (proliferation) Upregulated in breast cancer A, B
C-FOS NM_005252 3(s), 3(as) 17 AP-1 component Protooncogene A
ATF4 NM_001675 5(as) 369 Activating transcription factor Induced in breast cancer by A
(involved in hematopoietic cell heregulin
growth)
FOSL2 NM_005253 1(s), 1(as) 2 AP-1 component FOS-related A
MBD1 NM_015847 1(s), 1(as) 2 Methylated DNA binding protein, B
transcription inhibitor
HES6 XM_043579 1(s) 6 Transcription cofactor, B
differentiation inducer
NFB-1 NM_003998 1(as) 5 Transcription factor (stress, Upregulated in several types of A, B
apoptosis, proliferation) cancer
NR3C1 NM_000176 1(s) 5 Glucocorticoid receptor A
TAF7 XM_049114 1(s) 5 Transcription initiation factor A
JunB NM_002229 1(s) 4 AP-1 component Protooncogene B
Signal transduction
ARHG NM_001665 5(s), 1(as) 43 RhoG, small GTPase, cytoskeletal Ras family, interacts with ect2 A
reorganization oncogene, activates Rac1
PRKCH NM_006255 3(s), 2(as) 5 Serine/threonine protein kinase Stimulated by tumor promoters A, B
PRKCZ NM_002744 2(s), 1(as) 6 Serine/threonine protein kinase Stimulated by tumor promoters B
PRKCD NM_006254 2(s), 1(as) 5 Serine/threonine protein kinase Stimulated by tumor promoters C
AP1B1/BAM22 NM_001127 2(s) 5 Clathrin-associated adaptor A
protein
PPP2R1B NM_002716 2(as) 3 Protein phosphatase 2 regulatory Putative tumor suppressor B
subunit A
Rab5B NM_002868 2(as), 1(s), 3 Small GTPase, involved in vesicle Ras family C
1(as) transport
MAP2K2 NM_030662 2(as) 2 MAP kinase kinase Implicated in medulloblastoma A
metastasis
ZIN NM_013403 1(as) 6 Calmodulin-binding WD repeat A, B
protein
14-3-3 NM_145690 1(s) 2 14-3-3 protein, phospholipase A2 Regulates Raf B
Cell cycle progression genes
MCM-3 NM_002388 3(s), 4(as) 38 DNA replication C
FEN1 NM_004111 2(s), 2(as) 12 DNA replication and repair A
CCN D1 NM_001758 2(s), 2(as) 9 Cyclin, G1/S transition Amplified in cancers A
CDK2 NM_001798 2(s) 3 Cyclin-dependent kinase, Amplified in cancers A, B
S phase
CDK10 NM_003674 2(s) 2 Cell cycle, G2/M B
CDC20 NM_001255 1(as) 9 CDC2-related kinase, mitosis B
RPA3 NM_002947 1(s) 6 DNA replication, excision repair A
PCNA NM_002592 1(s) 3 DNA replication Upregulated in cancers C
Growth factors/growth factor receptors
EFN A1 NM_004428 1(s), 3(as) 9 Receptor tyrosine kinase ligand RAS pathway regulator A
FGFR1 NM_000604 2(s), 1(as) 6 Fibroblast growth factor receptor, Amplified in breast cancers A
tyrosine kinase
LynB NM_002350 2(as) 8 Tyrosine kinase YES protooncogene A
IGF2R NM_000876 2(s) 3 Insulin-like growth factor Mutated in breast cancers A, B
2 receptor
Cell adhesion
L1CAM NM_000425 8(s), 3(as) 20 Cell adhesion, neural A, B
ITG5 NM_002213 4(s), 1(as) 30 Cell adhesion, vitronectin A, B
receptor
ICAM2 NM_000873 2(s), 1(as) 8 Cell adhesion, intercellular A
ITG 4 NM_000885 1(s), 1(as) 4 Cell adhesion Involved in Src pathway B
Protein synthesis
EIF3S10 NM_003750 3(s) 3 Translation initiation factor 3, A
subunit 10
RPL31 NM_000993 2(s) 9 Ribosomal protein L31 Overexpressed in colorectal A, B
tumors
RPL35 NM_007209 2(as) 4 Ribosomal protein L35 C
KIAA1270 XM_044835 1(as) 9 Alanyl-tRNA synthetase homolog A
Protein processing
Hsp90 NM_005348 2(s) 27 Chaperone, protein folding Overexpressed in breast cancer, B
activates oncogenic tyrosine
kinases and Raf
(continued)
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Table 1. Continued
Accession # Sequences Functional
Gene Number (s/as) # clones Gene function Association with cancer assays*
ADPRT NM_001618 1(s), 1(as) 10 Poly (ADP ribosyl) transferase C
GRP58 NM_005313 1(s), 1(as) 4 Chaperone, interacts with STAT3 B
NIN283 NM_032268 1(s) 11 Lysosomal, putative role in protein A
ubiquitination
RNA processing and transport
HNRPF NM_004966 1(s) 5 Heterogeneous nuclear A, B
ribonucleoprotein F
HRPMT1L2 NM_001536 1(s) 5 Hnrp arginine methyltransferase- A, B
like 2
HNRPA2B1 NM_002137 1(s) 4 Heterogeneous nuclear A
ribonucleoprotein A2/B1
Others
VWF NM_000552 6(s), 5(as) 39 Blood clotting B
DAP-3 NM_004632 2(as) 3 Positive/negative apoptosis Overexpressed in gliomas A, B
regulator
MYL6 NM_021019 2(s) 2 Contractility A
IF1 NM_016311 1(s) 4 Inhibitor of Fo/F1 mitochondrial A
ATPase
Unknown function
GBC-1 NM_031221 2 (s) 70 Contains helical repeat peptide A, B
GBC-3 AA443027 1(s) 12 HC 3q29 A, B
GBC-11 1(s) 4 HC 14 A, B
GBC-12 1(s) 3 HC 1 A, B
GBC-13 1(s) 3 HC 16 B
* A, confirmed by BrdU suicide assay; B, gave rise to cell line inhibited by IPTG; C, low survival of infected cells.
selected cDNA fragments relative to the cDNA sequence and a mass population was previously observed with another BrdU-
selected growth inhibitor, ubiquitin-conjugating enzyme UbcM2to the corresponding protein domains for some of the enriched
genes. As shown in this figure, two related transcription factors (Pestov et al., 1998). To obviate this problem, we picked and
expanded 12 cell colonies from each GSE- or vector-transducedSTAT3 and STAT5b gave rise to clusters of fragments from the
tetramerization domain (involved in dimer-dimer interactions), cell population after BrdU selection. These clonal cell lines were
then individually tested for growth inhibition by IPTG. IPTG treat-and to a fragment of the SH2 domain that interacts with phos-
photyrosine residues. In another example, all eight sense-ori- ment neither affected the growth of untransduced cells in more
than 40 assays nor had any effect on the 12 cell lines transducedented GSEs of L1 cell adhesion molecule (L1CAM) mapped to
its immunoglobulin-like domains (IgGL), which are involved in with an insert-free vector. IPTG, however, inhibited the growth
of one or more cell lines carrying individual GSEs from 30 ofmultiple cis and trans interactions.
Selected cDNA fragments representing the 64 enriched the tested genes, with 17 genes giving rise to two or more IPTG-
inhibited lines. The results for some of these GSEs are showngenes were individually tested for biological activity in MDA-
MB231 cells, using two assays. In the first assay, LNXCO3 in Figure 3B. Figure 3C shows the time course of IPTG growth
inhibition in two of the selected cell lines; this growth inhibitionretroviruses carrying the tested sequences were transduced
into MDA-MB231-3SS31 cells, and the transduced populations was associated with the induction of GSE expression at the
RNA level in IPTG-treated cells (Figure 3D). Altogether, GSEswere tested for IPTG-dependent resistance to BrdU suicide.
from 51 genes have been confirmed so far by either one orIPTG had no effect on the survival of control cells transduced
both of the two assays. In addition, GSEs from 6 other geneswith insert-free LNXCO3 vector, but cDNA fragments derived
consistently yielded very few stably transduced cells, sug-from 38 genes have so far shown statistically significant and
gesting that even “leaky” basal-level expression of these GSEsreproducible increases in BrdU survival in the presence of IPTG
is growth-inhibitory.relative to its absence. Results of representative assays with a
subset of these GSEs are shown in Figure 3A.
In theory, IPTG-dependent survival of BrdU suicide selection Nature of the selected genes
Table 1 describes 57 genes that gave rise to growth-inhibitorycould result not only from growth inhibition by IPTG-regulated
GSEs but also from the ability of such GSEs to confer resistance GSEs, including 52 genes with known or tentative functions and
5 novel genes; the latter were designated GBC (for growth ofto the selective procedure through some other mechanism.
Therefore, in the second assay, we determined whether GSE breast cancer). Strikingly, close to 60% of these genes (33/57)
are already known to act as positive regulators of cell growthinduction by IPTG directly inhibits cell growth, a much more
stringent criterion than an increase in IPTG-dependent survival or neoplastic transformation, and some of the genes have been
implicated specifically in breast cancer (see Table 1), providingof BrdU suicide. In the initial experiments, IPTG produced no
significant growth inhibition in mass populations of GSE-trans- biological validation of our experimental strategy. These include
bona fide protooncogenes, such as C-FOS, JunB, and LynBduced cells, suggesting that GSE activity in most of the infected
cells was insufficient for this effect. The same lack of effect in (c-YES), as well as other growth-promoting genes that are ampli-
CANCER CELL : JULY 2003 45
A R T I C L E
fied in cancers, such as CCND1, CDK2, and FGFR1. Eight genes
in Table 1 are directly involved in cell cycle transitions or DNA
replication, and four other genes encode growth factors or
growth factor receptors.
The largest functional category of the selected genes in-
cludes 11 transcription regulatory proteins, some of which are
known to be involved in cell proliferation, including AP-1 compo-
nents C-FOS, FOSL2, and JUNB, and proliferation-promoting
factors STAT5b and STAT3, the latter of which is upregulated
in breast cancers (Garcia et al., 1997). Another highly enriched
transcription factor, ATF4, was recently shown to be a positive
regulator of hematopoietic cell proliferation (Masuoka and
Townes, 2002). ATF4 expression and function are augmented by
heregulin, a factor that stimulates the growth of breast cancers
(Talukder et al., 2000). Notably, ATF4 has been shown to dimer-
ize with Jun (Hai et al., 1999), and STAT3 and Jun were shown
to interact in regulating Fas expression (Ivanov et al., 2002). In
addition, concerted activation of STAT, AP-1, and NFB (an- Figure 4. Interactions of some of the gene products selected in the present
study in proliferation-associated signal transduction pathwaysother transcription factor that gave rise to growth-inhibitory
GSEs) was found to be a frequent and early event in human Several proteins that are not represented by the selected GSEs are shown
as unshaded symbols. The relations between different proteins in Figure 4 arehepatocellular carcinomas (Liu et al., 2002).
based on the following references: FGFR1-STAT (Hart et al., 2000; Smedley etTable 1 also includes ten regulators of signal transduction,
al., 1999), GRP58-STAT (Sehgal et al., 2002), LynB-PKC (Dibirdik et al., 1998;
many of which are involved in cell growth, including three iso- Joseloff et al., 2002), HSP90-Raf (Schulte et al., 1995), 14-3-3-Raf (Light et
forms of protein kinase C that mediates the tumor-promoting al., 2002), ERK-Fos (Wagstaff et al., 2000), Fos-Jun (Johnson et al., 2000), ERK-
ATF4 (Hayes and McMahon, 2001), Mek-ERK (Seddighzadeh et al., 1999),effect of phorbol esters, small GTPase ARHG (RhoG), and the
INT-Rho (Jo et al., 2002), FAK-Rho (Hildebrand et al., 1996), EFNA-INT (Huairegulatory subunit of protein phosphatase 2 (PPP2R1B). Al-
and Drescher, 2001), PP2-ERK (Kiguchi et al., 1992), LynB-STAT (Tilbrook etthough the latter gene is considered a putative tumor suppres-
al., 2001), L1CAM-FGFR (Williams et al., 1994).
sor, protein phosphatase 2 inhibitors were reported to induce
differentiation in breast carcinoma cell lines, including MDA-
MB231 (Kiguchi et al., 1992). Four other genes in Table 1 encode
cell adhesion molecules and integrins, which mediate intracellu- abnormalities, and similar neurological disorders have been re-
lar signaling, such as integrin 4 (ITGA4) that plays a role in the produced in L1CAM null mice, which show apparently normal
Src pathway. Remarkably, many of the identified genes interact development in other respects (Kamiguchi et al., 1998). This
with each other in signal transduction pathways that regulate limited biological function of L1CAM, combined with its frequent
the activities of transcription factors STAT, AP-1, and ATF4. expression in cancers and easy accessibility on the cell surface,
Such interactions are illustrated in Figure 4 for 17 proteins and make this molecule an interesting potential target for cancer
protein families identified in the present study. treatment. We have therefore investigated the effects of L1CAM
About 40% of the GSE-cognate genes have not been pre- inhibition in more detail.
viously implicated in cell growth, including five novel genes We have used a cell line that carries an IPTG-inducible
identified in the present study. Some genes in this category were sense-oriented GSE from L1CAM (Figure 2) and undergoes
among those that were most highly enriched by GSE selection growth inhibition upon GSE induction (Figures 3B and 3C) to
(Table 1), including von Willebrand factor (VWF) involved in blood determine if the GSE has an effect on L1CAM expression on
clotting, L1CAM, a cell adhesion molecule of immunoglobulin the cell surface. Concurrently, we have asked the same question
superfamily, integrin 5 (ITGB5), and novel gene GBC-1 that for a cell line carrying a GSE from another cell-surface protein,
contains a GSE-encoded helical repeat peptide and GBC-3, a integrin 5 (ITGB5). FACS analysis using L1CAM- and ITGB5-
gene from chromosome 3q29 with no detected homologies. specific antibodies (Figure 5A) demonstrated that induction of
How these novel genes regulate cell proliferation remains a both GSEs by IPTG decreased the amounts of their cognate
subject for future studies. proteins on the cell surface but had no effect on the expression
of the other protein. Interestingly, the GSE that inhibits ITGB5
Cellular effects of L1CAM inhibition expression is a sense-oriented fragment derived from the 5
One of the most highly enriched genes that has not been pre- untranslated region of the corresponding cDNA (Figure 2); the
viously implicated in cell proliferation encodes neural cell adhe- mechanism of action of this novel type of GSE remains to be
sion molecule L1CAM involved in signal transduction (Figure 4). determined.
L1CAM is expressed primarily in the brain, but its expression L1CAM GSE also induced pronounced changes in cell mor-
has also been seen in some other normal tissues and in several phology, leading to the formation of filopodia and apparent focal
types of cancer, including breast cancer (Perou et al., 2000). adhesion plaques (Figure 5B). Another reproducible morpholog-
L1CAM expression in malignant melanoma was found to corre- ical effect of L1CAM GSE induction was the appearance of cells
late with the metastatic phenotype (Thies et al., 2002), but to with fragmented or lobulated nuclei (Figure 5C). The fraction of
the best of our knowledge there is as yet no evidence that such micronucleated (MN) cells reached 8.3% after 7 days of
L1CAM plays any role in cell proliferation. Germline mutations IPTG treatment, as compared to 3.3% observed in this cell line
cultured for the same period of time in the absence of IPTG, orin human L1CAM have been associated with neural system
46 CANCER CELL : JULY 2003
A R T I C L E
Figure 5. Cellular effects of a GSE from L1CAM
A: FACS analysis of the binding of L1CAM or ITGB5-specific antibodies to the surface of cells expressing the L1CAM GSE (left) or ITGB5 GSE (right) indicated
in Figure 2, in the presence (thick lines) or absence (thin lines) of ITPG.
B: Morphological changes of cells expressing the L1CAM GSE in the absence (left) or presence (right) of ITPG, photographed using phase-contrast
microscopy at 100 magnification.
C: Micronuclei (MN) in cells expressing L1CAM GSE, in the presence of IPTG, photographed after DAPI staining at 400 magnification.
1.8% in vector-transduced cells (in the presence or absence of culture media at 20 nM resulted in 3- to 6-fold decrease in the
cell number of all four tumor cell lines relative to their corre-IPTG). These changes in nuclear morphology are characteristic
of mitotic catastrophe, a major form of tumor cell death, which sponding isotype controls, but the monoclonal antibodies pro-
duced little or no growth inhibition in any of the four normalis potentiated by various checkpoint deficiencies characteristic
of tumor cells (Roninson et al., 2001). This finding suggested cell cultures. The growth-inhibitory activity of both monoclonal
antibodies was abolished by heat denaturation (Figure 6B). Mi-that L1CAM inhibition has not only cytostatic but also cytotoxic
effect on breast carcinoma cells. croscopic examination of tumor cells remaining on the plate
after 4 days of incubation with anti-L1CAM monoclonal antibod-
ies showed the appearance of micronucleated or apoptoticL1CAM-specific antibodies inhibit the growth of
different tumor cell lines, but not normal cells cells, indicative of the induction of cell death (Figure 7). These
findings suggest that anti-L1CAM monoclonal antibodies orWe have investigated the effects of two different monoclonal
antibodies against the extracellular domain of L1CAM, UJ127, their derivatives may potentially be used as anticancer agents.
and 5G3 on the growth of MDA-MB231 and MCF-7 breast
carcinoma cell lines, HeLa cervical carcinoma and HCT116 co- GSE-cognate genes as potential drug targets
The example of L1CAM illustrates the utility of GSE-cognatelon carcinoma lines, telomerase-immortalized hTERT-BJ1 nor-
mal human fibroblasts, and three cultures of normal human genes as potential targets for future chemotherapeutic drugs.
In fact, some of these genes are already targeted by new drugsmammary epithelial cells (HMEC), 48RS, 184, and 161. All the
tumor cell lines as well as the normal hTERT-BJ1, 48RS, and that are entering the clinical armamentarium. These include
CCND1 and CDK2 targeted by small-molecule CDK inhibitors,184 cells expressed L1CAM on their surface as determined
by FACS analysis, but 161 HMEC cells showed no detectable and HSP90, a member of HSP90 family of chaperone proteins
(Csermely et al., 1998). While the chaperone function by itselfL1CAM (Figure 6A). In the experiment shown in Figure 6B, we
have investigated the effects of UJ127 and 5G3 antibodies, does not imply a role in cell growth, HSP90 was found to stabilize
several proteins involved in oncogenic pathways and to serve asnative or heat-denatured, as well as their corresponding isotype
controls, on the growth of all the cell lines for a period of four the target of an antitumor antibiotic geldanamycin. Furthermore,
HSP90 is expressed in several cancers (including breast) atdays, which corresponds to 1.9–2.5 population doublings (the
doubling times for each cell line are indicated in the legend to higher levels than in nonmalignant tissues (Csermely et al.,
1998). HSP90-inhibiting geldanamycin analog 17-AAG has beenFigure 6B). The addition of either UJ127 or 5G3 antibody to the
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Figure 6. Effects of monoclonal antibodies
against L1CAM on different types of tumor and
normal cells
A: FACS analysis of the binding of L1CAM-spe-
cific UJ127 antibody to the surface of the indi-
cated cell lines.
B: Effects of L1CAM-specific UJ127 (IgG1) and
5G3 (IgG2a) antibodies on the growth of MDA-
MB231 and MCF7 breast carcinomas, HCT116
colon carcinoma, HeLa cervical carcinoma,
hTERT-BJ1 normal immortalized fibroblasts, and
184, 161, and 48RS normal mammary epithelial
cell cultures. Cells were grown in the presence
of 20 nM of the antibodies or the corresponding
isotype controls, native or boiled (b), and
counted after 4 days (in triplicates). Each bar
represents the mean and standard deviation for
the number of cells in the presence of the indi-
cated antibodies relative to the isotype controls.
The doubling times for each cell line were as
follows: MDA-MB231, 42 hrs; MCF7, 41 hrs;
HCT116, 38 hrs; HeLa, 39 hrs; BJ1-hTERT, 50 hrs;
184, 41 hrs; 161, 42 hrs; 48RS, 51 hrs.
shown to arrest the growth of breast carcinoma cell lines includ- tial targets for anticancer drugs would be those genes that
are required for the growth of tumor but not normal cells. Theing MDA-MB231 (Munster et al., 2001), and it is currently in
clinical trial for breast cancer. apparent tumor specificity of growth inhibition by L1CAM anti-
bodies suggests that L1CAM belongs in this category of targets.Many of the genes implicated in tumor cell growth are also
likely to be essential for normal cells. The most promising poten- Indirect evidence from mouse knockout studies indicates that
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Figure 7. Induction of cell death by an antibody against L1CAM
Changes in nuclear morphology of tumor cells exposed for 4 days to 5G3 antibody, heat-inactivated (top) or native (bottom), photographed after DAPI
staining at 400 magnification. MN: micronucleated cells, A: apoptotic cells.
many other genes identified in the present study may also be ities. Although the effects of germline knockout are not equiva-
lent to those of protein inhibition in mature somatic cells, theseinessential for normal cells. The phenotypes of homozygous
knockout mice have been described in the literature for 20 of results suggest nevertheless that inhibitors of the latter genes
may not be growth-inhibitory for most of normal tissues. L1CAMthe GSE-cognate genes (Table 2). Although GSE-mediated inhi-
bition of these genes suppresses the growth of breast carci- and some of the other proteins with potentially tumor-specific
functions are found on the cell surface (ICAM2, ITGB5) or se-noma cells, the knockout of only six genes (STAT3, FGFR1,
IGF2R, ITGA4, JUNB, NR3C1) results in embryonic lethal pheno- creted (VWF), making the development of drugs targeting these
proteins relatively straightforward.type, indicating that these genes are required for the growth or
development of normal tissues. Mice null for L1CAM and 13 The nature of GSE selection used in the present study re-
quired that the GSEs induce reversible growth arrest rather thanother genes (CCND1, C-FOS, LYN, PRKCD, PRKCZ, PRKCH,
STAT5b, NFB-1, ATF4, ITGB5, ICAM2, VWF, and ADPRT) are cell death. This does not mean, however, that more potent drugs
targeting the GSE-cognate genes should have only cytostaticviable, with variable degrees of limited developmental abnormal-
Table 2. Phenotypes of Mice Null for GSE-Cognate Genes
Gene Accession # Mouse phenotype References
ATF4 NM_001675.1 Viable, severe microthalmia (Tanaka et al., 1998)
STAT5b NM_012448.1 Viable, loss of dimorphic GH signaling and cytokine (Udy et al., 1997)
responses
VWF NM_000552.2 Viable, circulatory and bleeding disorders (Denis et al., 1998)
ITGB5 NM_002213.1 Viable, fertile, impaired cell adhesion (Huang et al., 2000)
STAT3 NM_003150.1 Lethal during early embryogenesis (Takeda et al., 1997)
L1CAM NM_000425.2 Shorter lifespan than WT, malformed hindbrain (Dahme et al., 1997);
(Cohen et al., 1998)
C-FOS NM_005252.2 Viable, fertile, lack osteoclasts, lymphopenia (Johnson et al., 1992)
ADPRT NM_001618 Viable, increased sensitivity to radiation (Agarwal et al., 1997)
CCN D1 NM_001758.1 Viable, abnormal breast development (Sicinski et al., 1995)
ICAM2 NM_000873 Viable, lung inflammation (Sultan et al., 1997)
LYN NM_002350 Viable, splenomegaly (myeloid cells) (Chan et al., 1997)
FGFR1 NM_000604.2 Embryonic lethal, failure of mesoderm and endoderm (Ciruna et al., 1997)
formation
PKC NM_002744 Viable, fertile, malformed lymph glands (Leitges et al., 2001b)
NFB-1 NM_003998.1 Viable, fertile, decreased response to ionizing radiation (Sha et al., 1995)
NR3C1 NM_000176 Lethal perinatally (Cole et al., 1995)
PKC	 NM_006254.1 Viable, fertile, failure of apoptosis in muscle cells, (Leitges et al., 2001a)
increased arteriosclerosis
ITGA4 NM_000885 Embryonic lethal (Arroyo et al., 1996)
JunB NM_002229.1 Embryonic lethal (E8.5–10) (Schorpp-Kistner et
al., 1999)
PKC
 NM_006255.1 Viable, fertile, attenuated immune responses (Castrillo et al., 2001)
IGF2R NM_000876 Lethal perinatally (Ludwig et al., 1996)
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GSE selection and testingrather than cytotoxic activity. In fact, most of the cancer chemo-
MDA-MB231 cells were first modified by transduction with the murine eco-therapeutic drugs produce cytostatic inhibition at low doses
tropic receptor (Albritton et al., 1989) in retroviral vector LXIHis (Levensonand cell death at higher doses. Since most GSEs are relatively
et al., 1998). At the next stage, cells were transfected with the 3SS plasmid
weak inhibitors, one can expect them to mimic the cytostatic (Stratagene) that carries the LacI repressor and the hygromycin resistance
effects of low drug doses. We have previously investigated the marker and subcloned. 33 clonal cell lines were isolated and tested for IPTG-
mechanism of the cytostatic/cytotoxic transition in the case of regulated expression of a LacI-inhibited promoter. One of the tested cell
lines, called MDA-MB231-3SS31, showed about 80% infectability with eco-a human fibrosarcoma cell line with inducible expression of a
tropic retroviruses and 10-fold inducibility by IPTG. This line was chosen ascyclin-dependent kinase inhibitor p21Waf1/Cip1/Sdi1 (Chang et al.,
the recipient for GSE selection.2000). In that study, we observed that many cells that reenter
The normalized cDNA fragment library was converted into a mixture of
cell cycle after p21-induced cytostatic arrest die as a result of recombinant ecotropic retroviruses by transfection of BOSC-23 packaging
mitotic catastrophe. p21-induced abnormal mitosis was associ- cells, used to infect 2  108 MDA-MB231-3SS31 as described (Gudkov
ated with asynchronous resynthesis of different mitotic proteins, and Roninson, 1997), and the infectants were selected with G418. For BrdU
selection, 8  107 infected cells were plated at 106 per P150 and treatedleading to a failure of mitotic spindle checkpoint control, which
with 50 M IPTG for 36 hr, then with 50 M IPTG and 50 mM BrdU for 48is deficient in many tumor cell lines (Chang et al., 2000). The
hr. Cells were then incubated with 10 M Hoechst 33342 for 3 hr andfinding that some of the GSEs isolated in the present study,
illuminated with fluorescent white light for 15 min. Cells were washed twiceincluding L1CAM, induce not only cytostatic inhibition but also
with phosphate-buffered saline and allowed to recover in G418-containing
mitotic catastrophe indicates the cytotoxic potential of drugs medium without IPTG or BrdU, for 7–10 days. The surviving cells were
that will target the GSE-cognate genes. pooled, replated, and subjected to a second step of identical BrdU selection.
In summary, we have identified numerous genes that give The inserts of integrated proviruses were recovered by PCR from the
genomic DNA of the selected cells and recloned into the pLNXCO3 vectorrise to GSEs that inhibit the growth of human breast carcinoma
essentially as described in Gudkov and Roninson (1997); the specific primerscells and verified the growth-inhibitory activity of GSEs from 57
and procedures will be provided upon request. Sequence analysis of theof these genes by functional testing. The example of L1CAM
recovered inserts was carried out using an Applied Biosystems 3700 DNA
demonstrates that the inhibition of some GSE-cognate genes Analyzer (Foster City, CA). The analysis and attribution of the deduced se-
produces not only cytostatic but also cytotoxic effect, and that quences were carried out using BLAST alignment tool and BLASTMask
non-GSE agents targeting such genes may have a tumor-spe- program (which will be made available at our website at http://www2.uic.edu/
amaliy1/blastmask). Subsequent alignment and exclusion (masking) wascific growth inhibitory activity. Most of the identified genes were
carried out for Escherichia coli genome sequences, the NCBI UniVec vectorrepresented by several different GSE sequences; this redun-
segment database, the human Alu sequence database, and a set of rRNAdancy suggests that we have selected GSEs from the majority
and miscellaneous non-mRNA sequences. The partially masked dataset was
of genes that are amenable to BrdU suicide selection in MDA- then BLASTed against the RefSeq mammalian mRNA sequences. Se-
MB231 cells. The approach used in the present study is readily quences that contained unidentified stretches of at least 50 bp were then
applicable to other types of cancer and can also be used with selected by BLASTMask and sequentially BLASTed against NCBI’s NR, EST,
and HTGS databases. The BLAST hit data from databases containing humannormal cell cultures (such as telomerase-immortalized cell lines).
and mammalian sequences were combined and used by BLASTMask toExtension of this analysis should allow us to generate an exten-
group related GSE sequences with their gene attributions.sive database of genes that regulate the growth of different
For testing the GSE function by BrdU suicide survival assays, GSE-types of normal and tumor cells and to select potential new
transduced cell populations (200,000 per P100, in triplicate) were treated
targets for the treatment of cancer. with 50 M IPTG for 72 hr, then with 50 M IPTG and 50 M BrdU for 48
hr. A parallel set of cells was treated in the same way but without IPTG.
Experimental procedures Cells were then illuminated with white light in the presence of Hoechst 33342
and allowed to recover in the absence of BrdU and IPTG for 7–10 days,
Preparation of the normalized cDNA fragment library prior to scoring the surviving colonies. For testing the GSE function in clonal
PolyARNA was fragmented by heating at 100C for 9 min. Double-stranded lines of GSE-transduced cells by IPTG growth inhibition assay, such lines
cDNA was generated from this heat-fragmented RNA using the Gibco Super- were plated at 50,000 cells per P100 (in triplicates) and allowed to grow for
script kit with the reverse-transcription primer 5-GTGGATCCTCACTCACTC 7 days in the presence or absence of 500 M IPTG. Cell numbers were
ANNNNNNNN-3. This primer contains a random octamer sequence at its determined using a Coulter counter. To monitor the induction of GSE RNA
3 end for random priming, and it carries a unique sequence (termed “stop following addition of IPTG, RNA was extracted and analyzed by semiquanti-
adaptor”), which provides TGA stop codons in all three open reading frames tative reverse transcription-PCR (Noonan et al., 1990), using primers corre-
at the 3 end of cDNA fragments, as well as BamHI restriction site. The sponding to vector sequences flanking the GSE insert; -actin was used as
resulting double-stranded cDNA fragments were ligated to the following a normalization control.
adaptor: To determine the morphological effects of a GSE, IPTG-treated and
untreated cells were fixed in P100 plates with methanol/acetic acid (3:1),5-GTACCTGAGTTATAGGATCCCTGCCATGCCATGCCATG-3
stained with DAPI (5 mg/ml), and examined for blue fluorescence and under3-CCTAGGGACGGTACGGTACGGTAC-5
phase contrast, using a Leica inverted fluorescence microscope. The fraction
This “start adaptor” contains ATG translation initiation codons in all three of micronucleated cells was determined under phase contrast, by counting
frames, together with a BamHI site. The adaptor-tagged, double-stranded 500–1000 cells per sample.
cDNA was amplified by PCR with primers that anneal specifically to the start
and stop adaptors. Normalization of the PCR-amplified double-stranded Antibody assays
cDNA fragments was achieved by denaturing the cDNA fragments at 100C MDA-MB-231, MCF-7, and HeLa cells were purchased from the ATCC.
for 10 min and reannealing for 96 hr at 68C. Single-stranded cDNA fragments HTERT-BJ1 cell line was obtained from Clontech (Palo Alto, CA). Wild-type
were isolated after reannealing by hydroxyapatite chromatography, con- HCT116 cell line was a gift from Bert Vogelstein (Johns Hopkins Medical
verted to double-stranded fragments by PCR, and cloned into the Bgl II site Institutions, Baltimore, MD). Normal human mammary epithelial cell (HMEC)
of the LNXCO3 vector (Chang and Roninson, 1996). Normalization was cultures 184, 161 (both passage 7), and 48RS (passage 9), isolated from
established by Southern hybridization of PCR-amplified fragments and by reduction mammoplasty, were provided by Dr. Martha Stampfer (Lawrence
colony hybridization of plasmid library, using probes corresponding to actin, Berkeley National Labs, Berkeley, CA). HMECs were grown in MEGM, a
serum-free medium containing human epidermal growth factor (10 ng/ml),c-myc, c-fos, and mdr1 mRNA species.
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tion: a role for FGFR1 in morphogenetic movement through the primitiveinsulin (5 g/ml), hydrocortisone (0.5 g/ml), and bovine pituitary extract
streak. Development 124, 2829–2841.(Cambrex BioScience, Walkersville, MD). The other cell lines were grown in
DMEM with 10% fetal bovine serum. Monoclonal antibody to L1CAM from Cohen, N.R., Taylor, J.S., Scott, L.B., Guillery, R.W., Soriano, P., and Furley,
hybridoma 5G3 (IgG2a) was purchased from BD PharMingen (San Diego), A.J. (1998). Errors in corticospinal axon guidance in mice lacking the neural
and monoclonal antibody to L1CAM from hybridoma UJ127 (IgG1), as well cell adhesion molecule L1. Curr. Biol. 8, 26–33.
as nonimmune IgG1 and IgG2a, were purchased from NeoMarkers (Fremont,
Cole, T.J., Blendy, J.A., Monaghan, A.P., Krieglstein, K., Schmid, W., Aguzzi,CA). Rabbit polyclonal antibody against ITGB5 was from Chemicon (Teme-
A., Fantuzzi, G., Hummler, E., Unsicker, K., and Schutz, G. (1995). Targetedcula, CA). The corresponding secondary antibodies were labeled with fluo-
disruption of the glucocorticoid receptor gene blocks adrenergic chromaffinrescein isothiocyanate (Santa Cruz, CA). FACS analysis was carried out
cell development and severely retards lung maturation. Genes Dev. 9, 1608–using Becton Dickinson FACSort.
1621.For cell culture assays, azide-free monoclonal antibodies or isotype
controls were added to the media at the final concentration of 20 nM and Csermely, P., Schnaider, T., Soti, C., Prohaszka, Z., and Nardai, G. (1998).
sterilized with 0.22 micron polysulfone filters. As an additional control, mono- The 90-kDa molecular chaperone family: structure, function, and clinical
clonal antibodies were denatured by heating at 95C for 10 min in 0.1 ml applications. A comprehensive review. Pharmacol. Ther. 79, 129–168.
PBS. To determine the effect of anti-L1CAM monoclonal antibodies on cell
Dahme, M., Bartsch, U., Martini, R., Anliker, B., Schachner, M., and Mantei,growth and morphology, 10,000–20,000 cells were plated into each well of
N. (1997). Disruption of the mouse L1 gene leads to malformations of the24-well plates, and incubated at 37C for 4 days in the presence or absence
nervous system. Nat. Genet. 17, 346–349.of the corresponding antibody, with change of media after 2 days. Cell
growth was measured by counting the cell number (in triplicate) using a Denis, C., Methia, N., Frenette, P.S., Rayburn, H., Ullman-Cullere, M., Hynes,
Coulter counter. For nuclear morphology analysis, cells were fixed with R.O., and Wagner, D.D. (1998). A mouse model of severe von Willebrand
disease: defects in hemostasis and thrombosis. Proc. Natl. Acad. Sci. USAmethanol/acetic acid (5:1), stained with DAPI (5 g/ml in PBS), and examined
95, 9524–9529.for blue fluorescence and under phase contrast, using a Leica inverted
fluorescence microscope. Dibirdik, I., Kristupaitis, D., Kurosaki, T., Tuel-Ahlgren, L., Chu, A., Pond, D.,
Tuong, D., Luben, R., and Uckun, F.M. (1998). Stimulation of Src family
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